Contralateral prophylactic mastectomy for patients with unilateral breast cancer

References

• Robbins GF, Berg JW. Bilateral primary breast cancer: a prospective clinicopathological study. Cancer17, 1501–1527 (1964).
   PubMed Web of Science ®Google Scholar
• Storm HH, Jensen OM. Risk of contralateral breast cancer in Denmark 1943–1980. Br. J. Cancer54(3), 483–492 (1986).
   PubMed Web of Science ®Google Scholar
• Prior P, Waterhouse JA. The incidence of bilateral breast cancer: II: a proposed model for the analysis of coincidental tumours. Br. J. Cancer43(5), 615–622 (1981).
   PubMed Web of Science ®Google Scholar
• Adami HO, Bergstrom R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case–control study. Cancer55(3), 643–647 (1985).
   Google Scholar
• Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am. J. Surg.180(6), 439–445 (2000).
   PubMed Web of Science ®Google Scholar
• McDonnell SK, Schaid DJ, Myers JL et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J. Clin. Oncol.19(19), 3938–3943 (2001).
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Barlow WE, Yu O et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J. Clin. Oncol.23(19), 4275–4286 (2005).
   PubMed Web of Science ®Google Scholar
• van Sprundel TC, Schmidt MK, Rookus MA et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br. J. Cancer93(3), 287–292 (2005).
   PubMed Web of Science ®Google Scholar
• Gogas J, Markopoulos C, Skandalakis P, Gogas H. Bilateral breast cancer. Am. Surg.59(11), 733–735 (1993).
   Google Scholar
• Nielsen M, Christensen L, Andersen J. Contralateral cancerous breast lesions in women with clinical invasive breast carcinoma. Cancer57(5), 897–903 (1986).
   PubMed Web of Science ®Google Scholar
• Wanebo HJ, Senofsky GM, Fechner RE, Kaiser D, Lynn S, Paradies J. Bilateral breast cancer. Risk reduction by contralateral biopsy. Ann. Surg.201(6), 667–677 (1985).
   PubMed Web of Science ®Google Scholar
• Goldflam K, Hunt KK, Gershenwald JE et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer101(9), 1977–1986 (2004).
   PubMed Web of Science ®Google Scholar
• Slanetz PJ, Edmister WB, Yeh ED, Talele AC, Kopans DB. Occult contralateral breast carcinoma incidentally detected by breast magnetic resonance imaging. Breast J.8(3), 145–148 (2002).
   PubMedGoogle Scholar
• Lehman CD, Gatsonis C, Kuhl CK et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N. Engl. J. Med.356, 1295–303 (2007).
   PubMed Web of Science ®Google Scholar
• Liberman L. Breast MR imaging in assessing extent of disease. Magn. Reson. Imaging Clin. N. Am.14(3), 339–349, vi (2006).
   PubMedGoogle Scholar
• Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int. J. Radiat. Oncol. Biol. Phys.56(4), 1038–1045 (2003).
   PubMed Web of Science ®Google Scholar
• Fung MC, Schultz DJ, Solin LJ. Early-stage bilateral breast cancer treated with breast-conserving surgery and definitive irradiation: the University of Pennsylvania experience. Int. J. Radiat. Oncol. Biol. Phys.38(5), 959–967 (1997).
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet.62(3), 676–689 (1998).
   PubMed Web of Science ®Google Scholar
• Verhoog LC, Brekelmans CT, Seynaeve C et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet351(9099), 316–321 (1998).
   PubMed Web of Science ®Google Scholar
• Erdreich LS, Asal NR, Hoge AF. Morphologic types of breast cancer: age, bilaterality, and family history. South Med. J.73(1), 28–32 (1980).
   PubMed Web of Science ®Google Scholar
• Yeatman TJ, Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE. Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann. Surg. Oncol.4(3), 198–202 (1997).
   PubMed Web of Science ®Google Scholar
• Sacchini V, Pinotti JA, Barros AC et al. Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem? J. Am. Coll. Surg.203(5), 704–714 (2006).
   PubMed Web of Science ®Google Scholar
• Simmons RM, Brennan M, Christos P, King V, Osborne M. Analysis of nipple/areolar involvement with mastectomy: can the areola be preserved? Ann. Surg. Oncol.9(2), 165–168 (2002).
   PubMed Web of Science ®Google Scholar
• Boughey JC, Khakpour N, Meric-Bernstam F et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer107(7), 1440–1447 (2006).
   PubMed Web of Science ®Google Scholar
• King TA, Ganaraj A, Fey JV et al. Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy. Cancer101(5), 926–933 (2004).
   PubMed Web of Science ®Google Scholar
• Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst. Rev.(4), CD002748 (2004).
   Google Scholar
• Schrag D, Kuntz KM, Garger JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA283, 617–214 (2000).
   PubMed Web of Science ®Google Scholar
• Barton MB, West CN, Liu IL et al. Complications following bilateral prophylactic mastectomy. J. Natl Cancer Inst. Monogr.35, 61–66 (2005).
   Google Scholar
• Frost MH, Slezak JM, Tran NV et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J. Clin. Oncol.23(31), 7849–7856 (2005).
   PubMed Web of Science ®Google Scholar
• Montgomery LL, Tran KN, Heelan MC et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann. Surg. Oncol.6(6), 546–552 (1999).
   PubMed Web of Science ®Google Scholar
• Geiger AM, West CN, Nekhlyudov L et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J. Clin. Oncol.24(9), 1350–1356 (2006).
   PubMed Web of Science ®Google Scholar
• Tercyak KP, Peshkin BN, Brogan BM et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J. Clin. Oncol.25, 285–291 (2007).
   PubMed Web of Science ®Google Scholar
• Tuttle T, Habermann E, Grund E, Morris T, Virnig B. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. Presented at: Annual Meeting Society Surgical Oncology. Washington, DC, USA, 16 March 2007 (Abstract 19).
   Google Scholar
• Polednak AP. Frequency of prophylactic contralateral mastectomy among breast cancer patients. J. Am. Coll. Surg.192(6), 804–805 (2001).
   PubMedGoogle Scholar
• Nekhlyudov L, Bower M, Herrinton LJ et al. Women’s decision-making roles regarding contralateral prophylactic mastectomy. J. Natl Cancer Inst. Monogr.35, 55–60 (2005).
   Google Scholar
• Schwartz MD, Lerman C, Brogan B et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J. Clin. Oncol.22(10), 1823–1829 (2004).
   PubMed Web of Science ®Google Scholar
• Ciatto S, Ambrogetti D, Bonardi R, Bravetti P, Del Turco MR. Prognostic impact of early detection of contralateral primary breast cancer. Tumori76(4), 370–373 (1990).
   PubMed Web of Science ®Google Scholar
• Mellink WA, Holland R, Hendriks JH, Peeters PH, Rutgers EJ, van Daal WA. The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer67(7), 1844–1848 (1991).
   PubMed Web of Science ®Google Scholar
• Burns PE, Dabbs K, May C et al. Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Can. Med. Assoc. J.130(7), 881–886 (1984).
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J. Natl Cancer Inst.83(18), 1278–1280 (1991).
   PubMedGoogle Scholar
• Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J. Natl. Cancer Inst. Monogr.11, 117–120 (1992).
   PubMedGoogle Scholar
• Rutqvist LE, Cedermark B, Glas U et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J. Natl. Cancer Inst.83(18), 1299–1306 (1991).
   PubMed Web of Science ®Google Scholar
• Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case–control study. Hereditary Breast Cancer Clinical Study Group. Lancet356(9245), 1876–1881 (2000).
   PubMed Web of Science ®Google Scholar
• Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet359(9324), 2131–2139 (2002).
   PubMed Web of Science ®Google Scholar
• Meakin JW, Hayward JL, Panzarella T et al. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res. Treat.37(1), 11–19 (1996).
   PubMed Web of Science ®Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet351(9114), 1451–1467 (1998).
   PubMed Web of Science ®Google Scholar